Navigation Links
Synvista Therapeutics Announces Initiation of Phase 2 Study With Alagebrium for Chronic Heart Failure
Date:11/12/2007

MONTVALE, N.J., Nov. 12 /PRNewswire-FirstCall/ -- Synvista Therapeutics, Inc. (AMEX: SYI) announced today, dosing of the first patient in BENEFICIAL, a 100-patient Phase 2 clinical trial of alagebrium (ALT-711), a novel compound designed to act as an Advanced Glycation End-product (AGE)-cross-link breaker, in patients with chronic heart failure (CHF). The BENEFICIAL study (Double- blind, placebo-controlled, randomized trial evaluating the efficacy and safety of alagebrium) is designed to measure the effect of alagebrium on exercise tolerance in patients with CHF. The Company plans to use the experience and results of this study to guide development of its Phase 3 program for alagebrium in CHF. The single-site Phase 2 trial is being conducted at the University Medical Centre Groningen, The Netherlands and the principal investigator is Adriaan A. Voors, M.D., Associate Professor of Cardiology.

The objective of the BENEFICIAL study is to improve maximal oxygen consumption (VO2max), which is highly correlated with an improvement in myocardial function in patients with CHF. Diastolic and systolic function will be measured by tissue velocity imaging with echocardiography. The ability of alagebrium to break down AGEs will also be measured by tracking levels of carboxy-methyllysine (an AGE) in the skin using an auto-fluorescence device.

"Alagebrium is the first orally active AGE-cross-link breaker that has been evaluated in preclinical and clinical studies, and studies using animal models of diabetes and aging have demonstrated its effect in reversing cardiac stiffening," said Dr. Voors. "We are encouraged by the potential that alagebrium has demonstrated in our preclinical models, and are aggressively pursuing cli
'/>"/>

SOURCE Synvista Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Synvista Therapeutics Alagebrium Shows Potential for use in Treating Diabetes-Related Gastrointestinal Complications
2. Synvista Therapeutics Highlights New Data Demonstrating the Clinical Benefit of Vitamin E Therapy in Patients Identified on the Basis of Haptoglobin Phenotype Testing
3. Synvista Collaboration Demonstrates in Preclinical Studies the Mechanism for Defective Cholesterol Transport in Patients with Diabetes
4. Synvista Announces New Data Showing Haptoglobin Type Predicts Effectiveness of Tight Glycemic Control on Cardiovascular Outcomes in Patients with Diabetes
5. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
6. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
7. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
8. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
9. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
10. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
11. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... , May 4, 2015 Bayer HealthCare (Bayer) ... Pharmaceuticals, Inc. (NASDAQ: ISIS ) on ISIS-FXI Rx, ... the prevention of thrombosis. Under the agreement Bayer will ... of high unmet medical need. As part of the ... profile of ISIS-FXI Rx in an appropriate patient ...
(Date:5/4/2015)... LOS ANGELES , May 4, 2015 /PRNewswire/ ... research and development company specializing in oncology, today ... phase 1b aldoxorubicin combination studies pairing aldoxorubicin with ... doses of gemcitabine or ifosfamide with escalating doses ... tolerated, and even at the lowest dose level ...
(Date:5/4/2015)... 2015 Dyadic International, Inc. ("Dyadic") (OTCQX: ... proprietary technologies are used to develop, manufacture and ... bio-based chemical, biopharmaceutical and industrial enzyme industries, announced ... for quarter ending March 31, 2015 after market ... host a conference call that day at 5:00 ...
Breaking Medicine Technology:Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 2Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 3CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 2CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 3CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 4CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 5CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 6CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 7Dyadic International To Announce First Quarter 2015 Financial Results and Host Conference Call On Thursday, May 14, 2015 2Dyadic International To Announce First Quarter 2015 Financial Results and Host Conference Call On Thursday, May 14, 2015 3
(Date:5/4/2015)... NY (PRWEB) May 04, 2015 ... insurance programs, announces the expansion of coverage for its ... a leading provider of industry-tailored insurance and proactive risk ... & Company, we are dedicated to providing our customers ... meet their many evolving needs. We are excited to ...
(Date:5/4/2015)... TROY Healthcare Solutions is proud to be a sponsor ... Conference in Baltimore, MD from May 11 – 13, ... an opportunity for clients to gather to network, attend ... addition to sponsoring the event, TROY Healthcare Solutions will ... Attendees can stop by the TROY booth and see ...
(Date:5/4/2015)... May 04, 2015 Baptist Medical ... Stroke Association’s Get With The Guidelines®-Stroke Gold Plus ... Honor Roll. The award recognizes the hospital’s commitment ... the most appropriate treatment according to nationally recognized, ... , To receive the Gold Plus Quality Achievement ...
(Date:5/4/2015)... Now in its seventh year, the ... have made outstanding contributions to the company, to their ... acute and post-acute care settings. The five award categories ... the Year, Advanced Practice Clinician of the Year, Newcomer ... Year. Recipients are selected by IPC’s senior management team. ...
(Date:5/4/2015)... Angeles, CA (PRWEB) May 04, 2015 ... Sands, is now offering a more comfortable and attractive ... the restoration of choice for those who have lost ... Dentures can feel insecure or slip at the worst ... patient eats or talks. They can also painfully pinch ...
Breaking Medicine News(10 mins):Health News:Insurance Leader McNeil & Company Expands Coverage for Emergency Services Insurance Program (ESIP), Launches Enhancements to Property and Casualty Insurance Package 2Health News:Insurance Leader McNeil & Company Expands Coverage for Emergency Services Insurance Program (ESIP), Launches Enhancements to Property and Casualty Insurance Package 3Health News:TROY Healthcare to Exhibit at the Cerner North Atlantic Regional User Group Conference 2Health News:TROY Healthcare to Exhibit at the Cerner North Atlantic Regional User Group Conference 3Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 2Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 3Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 4Health News:IPC Healthcare Announces Clinicians of the Year 2Health News:IPC Healthcare Announces Clinicians of the Year 3Health News:Los Angeles Dental Implants Doctor, Kevin Sands DDS, Now Offers a More Comfortable and Aesthetically-Pleasing Solution to Denture-Wearers 2
... a blood clot that develops deep in the vein. It ... // ,People who require prolonged bed rest are ... ,especially patients in intensive care and patient on catheters are ... that in critically ill patients , a small pulmonary embolism, ...
... as age-related macular degeneration and cataracts may not live as ... A cataract involves the lens of the eye becoming cloudy ... 4,753 people aged 55 to 81, people with macular degeneration, ... 41-percent higher risk of death during the 6.5-year follow up ...
... show high levels of amino acid are associated with ... long been // associated with an increased risk of ... known to be associated with homocystinuria, a rare disease ... studies, high levels have also been found to be ...
... most common pulmonary lung function tests. It is used to ... the effectiveness // of treatment. The patient takes a deep ... the best of their ability. The spirometer measures both the ... expelled from the lungs.New research brings to light some common ...
... follicles undergo a growth cycle consisting of periods ... Researchers demonstrated that the brief activation of ?-catenin ... to initiate the anagen phase. Scientists have discovered ... ?-catenin can induce new hair growth. ...
... common chronic conditions affecting children in the United States. A ... infections in early childhood are more likely to be diagnosed ... and 11 years old. The complete medical history for each ... child and parents. It was found that children with a ...
Cached Medicine News:Health News:New Hair in 15 Days Could Now Be A Possibility Say Researchers 2
Aerosolized Medication Device for Infants. An alternative to aerosol blow-by., ,The PediNeb™ was designed to enhance the delivery of aerosolized medication, while reducing the apprehension enc...
... and Respiratory Products, ,Westmed designs, manufacturers ... Anesthesia and Respiratory professionals. Our mission is ... the clinician's ability to deliver quality medical ... bottom line. , ,Our web site ...
... Suggested Clinical Applications:, ,Cool Aerosol ... with open system devices such as aerosol ... masks that provide only limited FIO2 and ... Injection Nebulizer guards against accidental dilution with ...
... use with metered dose inhalers., ,ACE ... from MDI canisters. Its versatile design allows ... circuit, in conjunction with an endotracheal airway ... inhalation. ACE may also be used in ...
Medicine Products: